Annual EBIT
-$270.21 M
-$61.93 M-29.74%
March 31, 2024
Summary
- As of February 12, 2025, IMVT annual earnings before interest & taxes is -$270.21 million, with the most recent change of -$61.93 million (-29.74%) on March 31, 2024.
- During the last 3 years, IMVT annual EBIT has fallen by -$162.09 million (-149.92%).
- IMVT annual EBIT is now -311.49% below its all-time high of -$65.67 million, reached on March 31, 2020.
Performance
IMVT EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$114.30 M
+$1.44 M+1.24%
December 31, 2024
Summary
- As of February 12, 2025, IMVT quarterly earnings before interest & taxes is -$114.30 million, with the most recent change of +$1.44 million (+1.24%) on December 31, 2024.
- Over the past year, IMVT quarterly EBIT has dropped by -$52.75 million (-85.70%).
- IMVT quarterly EBIT is now -28575400.00% below its all-time high of -$400.00, reached on March 31, 2019.
Performance
IMVT Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$405.20 M
-$52.75 M-14.97%
December 31, 2024
Summary
- As of February 12, 2025, IMVT TTM earnings before interest & taxes is -$405.20 million, with the most recent change of -$52.75 million (-14.97%) on December 31, 2024.
- Over the past year, IMVT TTM EBIT has dropped by -$151.62 million (-59.79%).
- IMVT TTM EBIT is now -101301150.00% below its all-time high of -$400.00, reached on March 31, 2019.
Performance
IMVT TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
IMVT EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -29.7% | -85.7% | -59.8% |
| 3 y3 years | -149.9% | -176.9% | -194.2% |
| 5 y5 years | -311.5% | -956.4% | -3475.6% |
IMVT EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -149.9% | at low | -183.1% | +1.2% | -194.2% | at low |
| 5 y | 5-year | -311.5% | at low | -956.4% | +1.2% | -3475.6% | at low |
| alltime | all time | -311.5% | at low | <-9999.0% | +1.2% | <-9999.0% | at low |
Immunovant EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$114.30 M(-1.2%) | -$405.20 M(+15.0%) |
| Sep 2024 | - | -$115.74 M(+22.8%) | -$352.46 M(+18.1%) |
| Jun 2024 | - | -$94.28 M(+16.6%) | -$298.51 M(+10.5%) |
| Mar 2024 | -$270.21 M(+29.7%) | -$80.88 M(+31.4%) | -$270.21 M(+6.6%) |
| Dec 2023 | - | -$61.55 M(-0.4%) | -$253.59 M(+3.1%) |
| Sep 2023 | - | -$61.80 M(-6.3%) | -$246.06 M(+5.2%) |
| Jun 2023 | - | -$65.98 M(+2.7%) | -$233.88 M(+12.3%) |
| Mar 2023 | -$208.28 M(+33.5%) | -$64.26 M(+18.9%) | -$208.28 M(+8.9%) |
| Dec 2022 | - | -$54.03 M(+8.9%) | -$191.24 M(+7.1%) |
| Sep 2022 | - | -$49.61 M(+22.9%) | -$178.49 M(+7.2%) |
| Jun 2022 | - | -$40.38 M(-14.5%) | -$166.52 M(+6.7%) |
| Mar 2022 | -$156.03 M | -$47.23 M(+14.4%) | -$156.03 M(+13.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$41.27 M(+9.6%) | -$137.72 M(+7.5%) |
| Sep 2021 | - | -$37.65 M(+26.0%) | -$128.09 M(+15.0%) |
| Jun 2021 | - | -$29.89 M(+3.4%) | -$111.42 M(+3.1%) |
| Mar 2021 | -$108.12 M(+64.6%) | -$28.92 M(-8.6%) | -$108.12 M(+8.3%) |
| Dec 2020 | - | -$31.64 M(+50.9%) | -$99.81 M(+26.4%) |
| Sep 2020 | - | -$20.97 M(-21.1%) | -$78.99 M(+35.2%) |
| Jun 2020 | - | -$26.59 M(+29.0%) | -$58.44 M(+82.9%) |
| Mar 2020 | -$65.67 M | -$20.61 M(+90.5%) | -$31.94 M(+181.9%) |
| Dec 2019 | - | -$10.82 M(+2477.4%) | -$11.33 M(+2111.2%) |
| Sep 2019 | - | -$419.80 K(+354.8%) | -$512.50 K(+452.9%) |
| Jun 2019 | - | -$92.30 K(>+9900.0%) | -$92.70 K(>+9900.0%) |
| Mar 2019 | - | -$400.00 | -$400.00 |
FAQ
- What is Immunovant annual earnings before interest & taxes?
- What is the all time high annual EBIT for Immunovant?
- What is Immunovant annual EBIT year-on-year change?
- What is Immunovant quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Immunovant?
- What is Immunovant quarterly EBIT year-on-year change?
- What is Immunovant TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Immunovant?
- What is Immunovant TTM EBIT year-on-year change?
What is Immunovant annual earnings before interest & taxes?
The current annual EBIT of IMVT is -$270.21 M
What is the all time high annual EBIT for Immunovant?
Immunovant all-time high annual earnings before interest & taxes is -$65.67 M
What is Immunovant annual EBIT year-on-year change?
Over the past year, IMVT annual earnings before interest & taxes has changed by -$61.93 M (-29.74%)
What is Immunovant quarterly earnings before interest & taxes?
The current quarterly EBIT of IMVT is -$114.30 M
What is the all time high quarterly EBIT for Immunovant?
Immunovant all-time high quarterly earnings before interest & taxes is -$400.00
What is Immunovant quarterly EBIT year-on-year change?
Over the past year, IMVT quarterly earnings before interest & taxes has changed by -$52.75 M (-85.70%)
What is Immunovant TTM earnings before interest & taxes?
The current TTM EBIT of IMVT is -$405.20 M
What is the all time high TTM EBIT for Immunovant?
Immunovant all-time high TTM earnings before interest & taxes is -$400.00
What is Immunovant TTM EBIT year-on-year change?
Over the past year, IMVT TTM earnings before interest & taxes has changed by -$151.62 M (-59.79%)